Synairgen Share News (SNG)

LONDON (Dow Jones)--Synairgen PLC (SNG.LN), a respiratory drug discovery and development company with a particular focus on viral defense, Thursday reported a full year net loss of GBP2.6 million, compared with a loss of GBP2.5 million the previous year. MAIN FACTS: -Research and development expenditure for the year ended June 30 GBP2.1 million (2009: GBP2.1 million) -Loss per share 4.27 pence (2009: 10.64 pence) -Cash at June 30 GBP5.0 million (2009: GBP7.9 million) -During the forthcoming year, focus will be on progressing the asthma, influenza and COPD programs. -Shares closed Wednesday at 24.5 pence. -By Tommy Stubbington, Dow Jones Newswires; 44-20-7842-9268; tommy.stubbington@dowjones.com (END) Dow Jones Newswires July 29, 2010 02:56 ET (06:56 GMT)